Posted by Michael Wonder on 06 Sep 2021
Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm
6 September 2021 - Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its dealings with the company.
It has been a tough summer for the US FDA. After the unexpected departure of its vaccines heads, Congress is now demanding more information on the controversial accelerated approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab).
